Clinical Studies Define the Superiority of the Obagi Systems at the 63rd Annual American Academy of Dermatology Conference in New Orleans
63rd Annual American Academy of Dermatology Conference
LONG BEACH, Calif.--(BUSINESS WIRE)--Feb. 16, 2005--Obagi Medical Products (OMP) sponsors two new and exciting clinical studies at the upcoming 63rd Annual American Academy of Dermatology (AAD) Conference in New Orleans.
The first of the two studies highlights the results of a 24-week, 301 patient, clinical study of the OBAGI NU-DERM SYSTEM. A summary of the study indicates that the OBAGI NU-DERM SYSTEM is 2-3 times more effective than prescription drug regimens of tretinoin or hydroquinone, and 5-10 times more effective than top physician recommended over-the-counter (OTC) regimens. The results of this study will be on display at Exhibit P203 Friday, February 18th through Sunday, February 20th.
As a pioneer in the development of new approaches for treating skin disorders, Obagi Medical Products continually strives for innovative ways to study the skin's functions. The results of a recently completed study on photoluminescence (spectrofluorescence) of tryptophan levels in the skin demonstrate a noticeable treatment effect in photodamaged skin with use of both the OBAGI-C(TM) RX SYSTEM and the OBAGI NU-DERM SYSTEM. These results will be displayed at AAD Exhibit P1036.
Jose Ramirez, PhD of JR Chemical and S.J. Goldner, JD of Clinical Trial Associates of Michigan will be available at the poster exhibits for review and discussion of the study results. Additional information may be obtained at OMP booth #1539.
Based in Long Beach, CA, Obagi Medical Products develops, manufactures, markets and sells the leading brand of direct-to-physician skin care products in the United States under the OBAGI NU-DERM SYSTEM, OBAGI-C RX SYSTEM, CFFECTIVES and OBAGI BLUE PEEL labels. Obagi products are also well known in Japan, Scandinavia, Europe, Canada, Mexico and Central America, Latin America, the Middle East, and Southeast Asia.
